Lingxiang Yu

1.6k total citations
48 papers, 703 citations indexed

About

Lingxiang Yu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Lingxiang Yu has authored 48 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 14 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Lingxiang Yu's work include Spondyloarthritis Studies and Treatments (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and MicroRNA in disease regulation (6 papers). Lingxiang Yu is often cited by papers focused on Spondyloarthritis Studies and Treatments (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and MicroRNA in disease regulation (6 papers). Lingxiang Yu collaborates with scholars based in China, United States and Singapore. Lingxiang Yu's co-authors include Xiaodong Guo, Yanqiong Zhang, Na Lin, Zhiwei Li, Qiuyan Guo, Lu Xiong, Mei Yang, Zhiyan Li, Boan Li and Zhiwei Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lingxiang Yu

45 papers receiving 696 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lingxiang Yu China 16 397 284 92 84 65 48 703
Qun Zhang China 14 298 0.8× 206 0.7× 109 1.2× 78 0.9× 89 1.4× 57 736
Meng Guo China 16 315 0.8× 156 0.5× 107 1.2× 47 0.6× 76 1.2× 32 704
Sen Wei China 14 382 1.0× 141 0.5× 61 0.7× 83 1.0× 107 1.6× 26 663
Xuelan Zuo China 9 262 0.7× 136 0.5× 82 0.9× 46 0.5× 56 0.9× 25 516
Qiao Wang China 13 298 0.8× 269 0.9× 46 0.5× 51 0.6× 51 0.8× 26 549
Koki Sato Japan 8 489 1.2× 89 0.3× 115 1.3× 51 0.6× 57 0.9× 32 826
Yaling Li China 13 302 0.8× 211 0.7× 94 1.0× 71 0.8× 55 0.8× 40 572
Wei You China 15 358 0.9× 182 0.6× 84 0.9× 112 1.3× 77 1.2× 59 898
Zhihua Yang China 14 241 0.6× 106 0.4× 134 1.5× 58 0.7× 30 0.5× 34 521
Huei‐Sheng Huang Taiwan 17 430 1.1× 114 0.4× 82 0.9× 50 0.6× 57 0.9× 27 609

Countries citing papers authored by Lingxiang Yu

Since Specialization
Citations

This map shows the geographic impact of Lingxiang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingxiang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingxiang Yu more than expected).

Fields of papers citing papers by Lingxiang Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingxiang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingxiang Yu. The network helps show where Lingxiang Yu may publish in the future.

Co-authorship network of co-authors of Lingxiang Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Lingxiang Yu. A scholar is included among the top collaborators of Lingxiang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingxiang Yu. Lingxiang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yu, Lingxiang, et al.. (2023). Ankylosing spondylitis status and risk of secondary systemic amyloidosis: A two-sample mendelian randomization study. Human Immunology. 85(1). 110742–110742. 2 indexed citations
3.
Zhou, Tingting, Xinqi Wang, Lingxiang Yu, et al.. (2023). PRICKLE1 gene methylation and abnormal transcription in Chinese patients with ankylosing spondylitis. Immunobiology. 228(6). 152742–152742.
4.
Yan, Tao, Chen‐Yang Huang, Xuezhang Duan, et al.. (2023). A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Annals of Translational Medicine. 11(2). 109–109. 5 indexed citations
5.
6.
Ma, Zhaochen, Lingxiang Yu, Xia Mao, et al.. (2022). Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation. Experimental & Molecular Medicine. 54(9). 1536–1548. 28 indexed citations
7.
Zhang, Ge, Bowen Chen, Xiaobo Yang, et al.. (2022). Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study. World Journal of Gastroenterology. 28(41). 5968–5981. 8 indexed citations
8.
Yu, Lingxiang, Ming Shao, Yubo Ma, et al.. (2022). Relationship between meteorological factors and mortality from respiratory diseases in a subtropical humid region along the Yangtze River in China. Environmental Science and Pollution Research. 29(52). 78483–78498. 5 indexed citations
9.
Chen, Bowen, Lei Jin, Haitao Zhao, et al.. (2022). Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study. SHILAP Revista de lepidopterología. Volume 9. 1171–1185. 4 indexed citations
10.
Yan, Tao, Lingxiang Yu, Ning Zhang, et al.. (2022). The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biology and Medicine. 19(6). 1–16. 41 indexed citations
11.
Xu, Shanshan, Huang Li, Huimin Xie, et al.. (2021). Single nucleotide polymorphisms of TRAF2 and TRAF5 gene in ankylosing spondylitis: a case–control study. Clinical and Experimental Medicine. 21(4). 645–653. 4 indexed citations
12.
Xu, Shanshan, Zhipeng Pan, Huang Li, et al.. (2021). Association of FOXO3a gene polymorphisms and ankylosing spondylitis susceptibility in Eastern Chinese Han population. Gene. 800. 145832–145832. 4 indexed citations
13.
Yu, Lingxiang, Jixiang Deng, Xing Gao, et al.. (2021). Short-term effect of meteorological factors on the risk of rheumatoid arthritis hospital admissions: A distributed lag non-linear analysis in Hefei, China. Environmental Research. 207. 112168–112168. 20 indexed citations
14.
Shao, Ming, Lingxiang Yu, Changchun Xiao, et al.. (2021). Short-term effects of ambient temperature and pollutants on the mortality of respiratory diseases: A time-series analysis in Hefei, China. Ecotoxicology and Environmental Safety. 215. 112160–112160. 33 indexed citations
15.
Gan, Lu, Zhaojian Song, Yachun Zhang, et al.. (2021). Unique Glutelin Expression Patterns and Seed Endosperm Structure Facilitate Glutelin Accumulation in Polyploid Rice Seed. Rice. 14(1). 61–61. 22 indexed citations
16.
Lei, Guanglin, Hongxia Fan, Cheng Wang, et al.. (2020). Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma. World Journal of Gastroenterology. 27(1). 55–68. 2 indexed citations
17.
Yu, Lingxiang, Bolun Zhang, Muyi Yang, et al.. (2019). <p>MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2</p>. OncoTargets and Therapy. Volume 12. 5639–5647. 19 indexed citations
18.
Zhang, Jun, Zhiwei Xu, Lingxiang Yu, Meilan Chen, & Ke Li. (2014). Assessment of the Potential Diagnostic Value of Serum p53 Antibody for Cancer: A Meta-Analysis. PLoS ONE. 9(6). e99255–e99255. 22 indexed citations
19.
20.
Yu, Lingxiang, Liang Zhou, Mo Li, et al.. (2012). The Notch1/cyclooxygenase-2/Snail/E-cadherin pathway is associated with hypoxia-induced hepatocellular carcinoma cell invasion and migration. Oncology Reports. 29(1). 362–370. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qun Zhang Breakdown of academic impact, for papers by Meng Guo Breakdown of academic impact, for papers by Sen Wei Breakdown of academic impact, for papers by Xuelan Zuo Breakdown of academic impact, for papers by Qiao Wang Breakdown of academic impact, for papers by Koki Sato Breakdown of academic impact, for papers by Yaling Li Breakdown of academic impact, for papers by Wei You Breakdown of academic impact, for papers by Zhihua Yang Breakdown of academic impact, for papers by Huei‐Sheng Huang
Rankless by CCL
2026